Navigate

Useful links

We Accept

Contact us

Israel:
7 Gush Ezion st. Givat Shmuel
+972-3-9645 010

info@ascarit.com

Jerusalem:
19 Sultan Suliman st. Jerusalem 
+972-2-6261466

Germany:
+49-17628762003
germany@ascarit.com

Stay tuned

Connect with us

  • Facebook - White Circle
  • White LinkedIn Icon

 All rights in respect of the content and information on this site reserved to Ascarit Ltd. Copy and reproduction of the content of this website is forbidden without the express written permission of the company. All the information outlined by Ascarit Ltd in this site is not intended as a drug. This product is not intended to diagnose, treat, cure or prevent any disease. If you are under medical supervision, Please consult your doctor before use. To avoid any doubt, the information in this site is not intended to guide the public, serve as endorsement, instruction, or advice to use, Change the medical treatment you get and is not a substitute for consultation your physician / licensed therapist for advice. The URL address of this site does not constitute a recommendation or advice by a physician / licensed therapist. 

© 2016 All rights reserved to Ascarit Ltd.

Clinical trial

Clinical trials are biomedical research studies performed in people that follow a predefined set of procedures to test the safety and effectiveness of new treatments for diseases. Read on about Ascarx clinical trial data

Introduction

A clinical trial conducted on 119 patients with Type 2 diabetes mellitus, treated with conventional diabetic medicines, including insulin in some cases, showed the addition of Ascarx had a reducing and stabilising effect on blood sugar, HbA1c and lipid levels (LDL cholesterol and triglycerides) over the 12 week trial period. Additionally, in a significant number of cases, chronic complications associated with diabetes, such as impaired kidney function, sight, blood circulation or impotence appeared to improve.

119 patients enrolled

103 patients completed 12 weeks follow up

21 patients requested continued treatment with Ascarx

1 patient treated with Ascarx for 22 months

16 patients did not complete follow up to 12 weeks due to problems with:

* Flatulence or loose stools (4 patients)

* Poor adherence to protocol

* Taste of solution 

* Attending follow up

Results

Parameter

Value

(average)

After

12 weeks

Change

     %

Glucose

211 mg/dl

133 mg/dl

- 34%

HbA1c

9.1%

7.1%

- 22%

Triglycerides

266 mg/dl

160 mg/dl

- 24%

Total Cholestrol

212 mg/dl

185 mg/dl

- 13%

LDL

Reduced in 81% of the patients

HDL

Increased 51.3% of the patients

Glucose

0   

Months

3

HbA1c

Months

3

0